Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

DNA binding mode of transition metal complexes, a relationship to tumor cell toxicity.

Ashfaq M, Najam T, Shah SS, Ahmad MM, Shaheen S, Tabassum R, Rivera G.

Curr Med Chem. 2014;21(26):3081-94. Review.

PMID:
24934346
2.

DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.

Brabec V, Nováková O.

Drug Resist Updat. 2006 Jun;9(3):111-22. Epub 2006 Jun 21. Review.

PMID:
16790363
3.

Copper compounds in cancer chemotherapy.

Ruiz-Azuara L, Bravo-Gómez ME.

Curr Med Chem. 2010;17(31):3606-15. Review.

PMID:
20846116
4.

Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs.

Liu W, Gust R.

Chem Soc Rev. 2013 Jan 21;42(2):755-73. doi: 10.1039/c2cs35314h. Review.

5.

Terpyridines and their complexes with first row transition metal ions: cytotoxicity, nuclease activity and self-assembly of biomacromolecules.

Winter A, Gottschaldt M, Newkome GR, Schubert US.

Curr Top Med Chem. 2012;12(3):158-75. Review.

PMID:
22236160
6.

Fresh platinum complexes with promising antitumor activity.

Wang X.

Anticancer Agents Med Chem. 2010 Jun;10(5):396-411. Review.

PMID:
20545618
7.

Metal complexes with aromatic N-containing ligands as potential agents in cancer treatment.

Zhao G, Lin H.

Curr Med Chem Anticancer Agents. 2005 Mar;5(2):137-47. Review.

PMID:
15777221
8.

New platinum antitumor complexes.

Kelland LR.

Crit Rev Oncol Hematol. 1993 Dec;15(3):191-219. Review.

PMID:
8142057
9.

Next-generation anticancer metallodrugs.

Komeda S, Casini A.

Curr Top Med Chem. 2012;12(3):219-35. Review.

PMID:
22236158
11.

Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells.

Alvarez-Valdés A, Pérez JM, López-Solera I, Lannegrand R, Continente JM, Amo-Ochoa P, Camazón MJ, Solans X, Font-Bardía M, Navarro-Ranninger C.

J Med Chem. 2002 Apr 25;45(9):1835-44.

PMID:
11960495
12.

Transition Metal Intercalators as Anticancer Agents-Recent Advances.

Deo KM, Pages BJ, Ang DL, Gordon CP, Aldrich-Wright JR.

Int J Mol Sci. 2016 Oct 31;17(11). pii: E1818. Review.

13.

Transition metal based anticancer drugs.

Garbutcheon-Singh KB, Grant MP, Harper BW, Krause-Heuer AM, Manohar M, Orkey N, Aldrich-Wright JR.

Curr Top Med Chem. 2011;11(5):521-42. Review.

PMID:
21189131
14.

New metal complexes as potential therapeutics.

Zhang CX, Lippard SJ.

Curr Opin Chem Biol. 2003 Aug;7(4):481-9. Review.

PMID:
12941423
15.

Carbohydrate-metal complexes and their potential as anticancer agents.

Hartinger CG, Nazarov AA, Ashraf SM, Dyson PJ, Keppler BK.

Curr Med Chem. 2008;15(25):2574-91. Review.

PMID:
18855680
16.

Non-classical structures among current platinum complexes with potential as antitumor drugs.

G Quiroga A.

Curr Top Med Chem. 2011;11(21):2613-22. Review.

PMID:
22039872
17.

Beyond platinums: gold complexes as anticancer agents.

Nardon C, Boscutti G, Fregona D.

Anticancer Res. 2014 Jan;34(1):487-92. Review.

PMID:
24403506
18.

The effect of antitumor trans-[PtCl2(E-iminoether)2] on B-->Z transition in DNA.

Zaludová R, Natile G, Brabec V.

Anticancer Drug Des. 1997 Jun;12(4):295-309.

PMID:
9199661
19.

Cellular response to antitumor cis-Dichlorido platinum(II) complexes of CDK inhibitor Bohemine and its analogues.

Liskova B, Zerzankova L, Novakova O, Kostrhunova H, Travnicek Z, Brabec V.

Chem Res Toxicol. 2012 Feb 20;25(2):500-9. doi: 10.1021/tx200525n. Epub 2012 Feb 1.

PMID:
22250642
20.

Synthesis, interaction with DNA and bovine serum albumin of the transition metal complexes of demethylcantharate and 2-aminobenzothiazole.

Zhang F, Lin QY, Li SK, Zhao YL, Wang PP, Chen MM.

Spectrochim Acta A Mol Biomol Spectrosc. 2012 Dec;98:436-43. doi: 10.1016/j.saa.2012.08.074. Epub 2012 Aug 31.

PMID:
22995471

Supplemental Content

Support Center